Expression of estrogen receptors (α, β), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Advances in Medical Sciences

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2478/v10039-012-0055-1PMID 23625281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells.

  2012cited by this paper
• Developments in the systemic treatment of endometrial cancer.

  2011cited by this paper
• Obesity and Women's Health: An Evidence-Based Review

  2011cited by this paper
• Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis.

  2011cited by this paper
• Current role and safety profile of aromatase inhibitors in early breast cancer

  2011cited by this paper
• Endometrial cancer: reviving progesterone therapy in the molecular age.

  2011cited by this paper
• Evolution in Endometrial Cancer: Evidence From an Immunohistochemical Study

  2011cited by this paper
• Endometrial cancer, types, prognosis, female hormones and antihormones

  2011cited by this paper
• Progesterone receptor gene variants and risk of endometrial cancer.

  2011cited by this paper
• Early life environment, life history and risk of endometrial cancer.

  2011cited by this paper
• Progesterone: the ultimate endometrial tumor suppressor.

  2011cited by this paper
• Diabetes, Gestational Diabetes and the Risk of Cancer in Women: Epidemiologic Evidence and Possible Biologic Mechanisms

  2011cited by this paper
• ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcinogenesis in endometrial cancer.

  2011cited by this paper
• Inhibition of estrogen actions in human gynecological malignancies: new aspects of endocrine therapy for endometrial cancer and ovarian cancer.

  2011cited by this paper
• Body mass index of patients with endometrial hyperplasia: comparison to patients with proliferative endometrium and abnormal bleeding.

  2011cited by this paper
• Evaluation of the Proportion of Hormonal and Progenotoxic Effects of Estrogens and Glucose in Cancer Patients

  2010cited by this paper
• The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma.

  2010cited by this paper
• The relationship of COX–2 expression with estrogen receptor, progesterone receptor and prognostic parameters in endometrial carcinomas

  2010cited by this paper
• Hormone prevention strategies for breast, endometrial and ovarian cancers.

  2010cited by this paper
• Estimating the Risk of Endometrial Cancer in Symptomatic Postmenopausal Women: A Novel Clinical Prediction Model Based on Patients' Characteristics

  2010cited by this paper
• Aromatase, Cyclooxygenase 2, HER-2/neu, and P53 as Prognostic Factors in Endometrioid Endometrial Cancer

  2009cited by this paper
• Obesity management--an opportunity for cancer prevention.

  2009cited by this paper
• Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome.

  2009cited by this paper
• Estrogen Sulfotransferases in Breast and Endometrial Cancers

  2009cited by this paper
• Endocervical Adenocarcinomas With Prominent Endometrial or Endomyometrial Involvement Simulating Primary Endometrial Carcinomas: Utility of HPV DNA Detection and Immunohistochemical Expression of p16 and Hormone Receptors to Confirm the Cervical Origin of the Corpus Tumor

  2009cited by this paper
• Long-term “protective” effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients

  2008cited by this paper
• Aromatase inhibitors and the endometrium.

  2008cited by this paper
• Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.

  2008cited by this paper
• Preventive effects of glycyrrhizin on estrogen-related endometrial carcinogenesis in mice.

  2007cited by this paper
• Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.

  2007cited by this paper
• Endometrial carcinosarcoma presenting as a tibial metastasis

  2007cited by this paper
• Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.

  2007cited by this paper
• Peroxisome Proliferator-Activated Receptor γ and Growth Inhibition by Its Ligands in Uterine Endometrial Carcinoma

  2006cited by this paper
• Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes.

  2006cited by this paper
• Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer.

  2006cited by this paper
• Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.

  2005cited by this paper
• Aromatase and comparative response to its inhibitors in two types of endometrial cancer.

  2005cited by this paper
• Aromatase Expression in Stromal Cells of Endometrioid Endometrial Cancer Correlates with Poor Survival

  2005cited by this paper
• Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.

  2005cited by this paper
• [Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma].

  2005cited by this paper
• Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.

  2005cited by this paper
• The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer.

  2003cited by this paper
• Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

  2002cited by this paper
• Cyclooxygenase‐2 expression in endometrial carcinoma

  2002cited by this paper
• Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.

  2002cited by this paper
• [Aromatase (P450AROM) mRNA expression in normal, hyperplastic and malignant endometrium and aromatase activity in endometrial cancer tissue culture].

  2000cited by this paper
• Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma.

  2000cited by this paper
• Treatment of human endometrial gland epithelial cells with chorionic gonadotropin/luteinizing hormone increases the expression of the cyclooxygenase-2 gene.

  1999cited by this paper
• Two pathogenetic types of endometrial carcinoma.

  1983cited by this paper

• Methimazole-Induced Hypothyroidism Increases the Content of Glycogen and Changes the Expression of LDH, GLUT4, and Aromatase in the Pregnant Uterus of Rabbits

  2025cites this paper
• Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer.

  2025cites this paper
• Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer

  2023cites this paper
• The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer

  2023cites this paper
• Roles of estrogen receptor α and β in the regulation of proliferation in endometrial carcinoma.

  2020cites this paper
• Knockdown of estrogen receptor β increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells

  2019cites this paper
• Macrophage ERα promoted invasion of endometrial cancer cell by mTOR/KIF5B‐mediated epithelial to mesenchymal transition

  2019cites this paper
• To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor

  2018cites this paper
• Integrated eicosanoid lipidomics and gene expression reveal decreased prostaglandin catabolism and increased 5‐lipoxygenase expression in aggressive subtypes of endometrial cancer

  2018cites this paper
• Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery

  2018cites this paper
• Preparation and Characterization of Celecoxib-Conjugated Polyethylenimine as a Potential Nanocarrier for Gene Delivery

  2018cites this paper
• Association of the G/T rs4646 of CYP19 gene polymorphism with oxidative stress, vitamin A and estradiol in Iraqi women with endometriosis disease

  2018cites this paper
• Multiple receptors shape the estrogen response pathway and are critical considerations for the future of in vitro-based risk assessment efforts

  2017cites this paper
• Reversal of cisplatin resistance in ovarian cancer cells mediated by naringin-induced COX-2 expression through the NF-κB signaling pathway

  2017cites this paper
• Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma

  2017cites this paper
• The significance of markers in the diagnosis of endometrial cancer

  2016cites this paper
• Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: A systematic review and meta-analysis of observational studies.

  2016cites this paper
• Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.

  2016cites this paper
• Differential expression of upstream stimulatory factor (USF) 2 variants in eutopic endometria from women with endometriosis: estradiol regulation

  2015cites this paper
• Aromatase Inhibitors Beyond Breast Cancer: Endometrium Versus Breast Puzzle and Other Issues

  2015cites this paper
• Morphological and ultrasound characteristics of endometrium in patients with breast cancer and the risk of secondary tumors

  2015cites this paper
• Estrogen receptor β: the guardian of the endometrium.

  2015cites this paper
• Sensitivity of endometrial cancer cells from primary human tumor samples to new potential anticancer peptide lactaptin.

  2015cites this paper
• Investigation of Aromatase in Endometrial Hyperplasia in the Polycystic Ovary Syndrome

  2014cites this paper
• Changes in the subcellular and tissue location of estrogen and progesterone receptors in rat uterus after long-term treatment with analogs of gonadoliberin.

  2014cites this paper
• miR-22 inhibits proliferation and invasion in estrogen receptor α-positive endometrial endometrioid carcinomas cells.

  2014cites this paper
• Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases.

  2014cites this paper
• Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology

  2013cites this paper